LONDON (dpa-AFX) – On Wednesday, Alexion Pharma Canada Corp., AstraZeneca's rare disease group, signed a memorandum of understanding with the pan-Canadian Pharmaceutical Alliance for Koselugo to treat pediatric patients aged two years and older with neurofibromatosis type 1 or NF1 who have symptomatic, unresectable plexiform neurofibromas.
NF1 is a rare, progressive genetic disorder that causes symptoms such as soft lumps on and under the skin.
The company said that selumetinib, sold under the name Koselugo, slows the growth of tumor cells and is approved in the US, EU, Japan, China and other countries for the treatment of certain pediatric patients with NF1.
Under the agreement, individual provinces and territories can now begin the process of adding Koselugo to their forms.
“The positive conclusion of this agreement between Alexion and pCPA is very exciting news for Canadian children and their families living with NF1 PN,” said Veronique Maheux, President of L'Association de la Neurofibromatosis du Quebec.
“I would also like to thank the Province of Quebec for its leadership in being the first to add Koselugo to the list, and call on other provinces and territories to make Koselugo available to children with NF1 PN as quickly as possible.”
Currently, AstraZeneca shares are trading at $65.90, down 1.90 percent on the Nasdaq.
Copyright(c) 2024 RTTNews.com. All rights reserved
Copyright RTT News/dpa-AFX
